[
    {
        "id": "dashboard-item-1759853783245-patient-context",
        "type": "component",
        "x": -4029,
        "y": 3700,
        "width": 1600,
        "height": "auto",
        "componentType": "PatientContext",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Patient Context",
            "component": "PatientContext",
            "props": {
                "patientData": {
                    "patient": {
                        "name": "Sarah Miller",
                        "date_of_birth": "1981-06-03",
                        "age": 43,
                        "sex": "Female",
                        "age_at_first_encounter": 43,
                        "identifiers": {
                            "mrn": "SM43850603"
                        }
                    },
                    "riskLevel": "high",
                    "primaryDiagnosis": "Severe Drug-Induced Liver Injury (Methotrexate-related)",
                    "problem_list": [
                        {
                            "name": "Type 2 Diabetes Mellitus",
                            "status": "active"
                        },
                        {
                            "name": "Essential Hypertension",
                            "status": "active"
                        },
                        {
                            "name": "Rheumatoid Arthritis",
                            "status": "active"
                        },
                        {
                            "name": "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/MASH)",
                            "status": "active"
                        },
                        {
                            "name": "Severe Methotrexate-induced Drug-Induced Liver Injury (DILI)",
                            "status": "active"
                        },
                        {
                            "name": "Acute jaundice episode (2024-08)",
                            "status": "resolved/improving"
                        }
                    ],
                    "medication_timeline": [
                        {
                            "name": "Metformin",
                            "dose": "1000 mg",
                            "route": "PO",
                            "frequency": "BD",
                            "start": "2019-01-01"
                        },
                        {
                            "name": "Ramipril",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "daily",
                            "start": "2020-01-01"
                        },
                        {
                            "name": "Ibuprofen",
                            "dose": "variable",
                            "route": "PO",
                            "frequency": "PRN",
                            "start": "2022-01-01"
                        },
                        {
                            "name": "Simethicone",
                            "dose": "standard",
                            "route": "PO",
                            "frequency": "PRN",
                            "start": "2024-03-05"
                        },
                        {
                            "name": "Methotrexate",
                            "dose": "7.5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-06-03",
                            "end": "2024-08-12"
                        },
                        {
                            "name": "Folic Acid",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-06-03"
                        },
                        {
                            "name": "Methotrexate (dose reduced)",
                            "dose": "5 mg",
                            "route": "PO",
                            "frequency": "weekly",
                            "start": "2024-07-15",
                            "end": "2024-08-12"
                        },
                        {
                            "name": "N-Acetylcysteine (NAC IV)",
                            "dose": "3-bag protocol",
                            "route": "IV",
                            "frequency": "one-time protocol",
                            "start": "2024-08-12",
                            "end": "2024-08-17"
                        },
                        {
                            "name": "Ursodeoxycholic Acid (UDCA)",
                            "dose": "500 mg",
                            "route": "PO",
                            "frequency": "BID",
                            "start": "2024-08-15"
                        }
                    ],
                    "allergies": [
                        "Methotrexate (severe DILI \u2013 permanent contraindication)"
                    ]
                }
            }
        },
        "createdAt": "2025-10-14T16:16:23.245Z",
        "updatedAt": "2025-11-21T08:36:27.123Z"
    },
    {
        "id": "dashboard-item-1759906219477-adverse-event-analytics",
        "type": "component",
        "x": -4031,
        "y": 4444,
        "width": 1600,
        "height": "auto",
        "componentType": "AdverseEventAnalytics",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Adverse Event Analytics",
            "component": "AdverseEventAnalytics",
            "props": {
                "patientData": {
                    "adverseEvents": [
                        {
                            "event": "Drug-Induced Liver Injury (DILI)",
                            "severity": "Severe",
                            "description": "Severe hepatocellular DILI caused by Methotrexate, presenting with ALT 490 U/L (12\u00d7 ULN), AST 350 U/L, and progressive jaundice."
                        },
                        {
                            "event": "Cholestatic Jaundice",
                            "severity": "Severe",
                            "description": "Bilirubin elevation from 110 to 190 \u03bcmol/L with marked jaundice; consistent with cholestatic component of acute DILI."
                        },
                        {
                            "event": "Methotrexate Toxicity",
                            "severity": "Severe",
                            "description": "Progressive hepatotoxicity after MTX initiation; ALT 185 U/L within 6 weeks; continued exposure led to severe acute DILI requiring hospitalization."
                        },
                        {
                            "event": "Acute-on-Chronic Liver Injury",
                            "severity": "Moderate\u2013Severe",
                            "description": "Acute hepatocellular necrosis superimposed on underlying MASLD/MASH, demonstrated by coarse echogenic liver on ultrasound."
                        }
                    ],
                    "rucam_ctcae_analysis": {
                        "rucam": {
                            "title": "RUCAM Scoring (Hepatocellular Pattern)",
                            "columns": [
                                "#",
                                "Parameter",
                                "Key findings from this case",
                                "Score",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "1",
                                    "Time to onset (from drug start to injury)",
                                    "MTX started 2024-06-03 \u2192 ALT rise noted by 2024-07-15 (~6 weeks)",
                                    "+2",
                                    "Typical 5\u201390 day window for idiosyncratic hepatocellular DILI."
                                ],
                                [
                                    "2",
                                    "Course after stopping the drug",
                                    "ALT decreased from 490 \u2192 420 U/L by 2024-08-15 post-MTX cessation",
                                    "+3",
                                    "Fall \u226550% within 8 days supports drug causality."
                                ],
                                [
                                    "3",
                                    "Risk factors",
                                    "Female (+0), Age 43 (+0), underlying MASLD",
                                    "0",
                                    "Neither age nor sex adds RUCAM points; MASLD is a cofactor but not scored."
                                ],
                                [
                                    "4",
                                    "Concomitant drugs",
                                    "Metformin, Ramipril, Ibuprofen (non-hepatotoxic at recorded doses)",
                                    "0",
                                    "No confounding hepatotoxic co-medication recorded."
                                ],
                                [
                                    "5",
                                    "Exclusion of non-drug causes",
                                    "Negative viral serology, negative ANA/ASMA, no biliary obstruction on ultrasound",
                                    "+2",
                                    "Competing etiologies reasonably excluded."
                                ],
                                [
                                    "6",
                                    "Previous information on hepatotoxicity",
                                    "Methotrexate well-recognized hepatotoxin with documented DILI cases",
                                    "+2",
                                    "Established hepatotoxic risk."
                                ],
                                [
                                    "7",
                                    "Response to re-exposure",
                                    "Not applicable (no re-challenge)",
                                    "0",
                                    "---"
                                ]
                            ],
                            "total_score": 9,
                            "causality_category": "Highly Probable"
                        },
                        "ctcae": {
                            "title": "CTCAE Hepatic Toxicity Scoring",
                            "columns": [
                                "Criterion",
                                "Observed / Inferred",
                                "CTCAE Grade",
                                "Explanation"
                            ],
                            "rows": [
                                [
                                    "ALT/AST",
                                    "ALT 490 U/L (\u224812\u00d7 ULN), AST 350 U/L",
                                    "Grade 3",
                                    "ALT 5\u201320\u00d7 ULN = Grade 3 severity."
                                ],
                                [
                                    "Total Bilirubin",
                                    "Bilirubin peaked at 190 \u03bcmol/L (\u224811 mg/dL)",
                                    "Grade 3",
                                    ">3\u00d7 ULN and clinical jaundice."
                                ],
                                [
                                    "INR / Coagulopathy",
                                    "INR remained 1.05\u20131.1 (normal)",
                                    "Grade 1",
                                    "No synthetic dysfunction; cannot qualify as Grade 4."
                                ],
                                [
                                    "Clinical Presentation",
                                    "Severe nausea, anorexia, jaundice; no hepatic encephalopathy",
                                    "Grade 2\u20133",
                                    "Significant symptoms without CNS involvement."
                                ]
                            ],
                            "overall_grade": "CTCAE Grade 3 \u2014 Severe but not life-threatening (no ALF or encephalopathy)"
                        },
                        "reasoning": "The patient developed acute severe hepatocellular DILI approximately 6 weeks after initiating Methotrexate. The trajectory shows progressive rise in ALT from 35 to 185 to 490 U/L, accompanied by marked jaundice and cholestasis. Viral, autoimmune, and biliary causes were excluded. INR remained stable and GCS remained 15 throughout hospitalization, confirming absence of acute liver failure. Ultrasound demonstrated severe MASLD, indicating chronic vulnerability. RUCAM score is 9 (highly probable). CTCAE grading corresponds to Grade 3 hepatic injury due to elevated bilirubin and transaminases without synthetic failure. Management appropriately included immediate MTX cessation, IV NAC protocol, hepatology admission, and initiation of UDCA."
                    }
                }
            }
        },
        "createdAt": "2025-10-14T16:50:19.477Z",
        "updatedAt": "2025-11-21T08:36:24.123Z"
    },
    {
        "id": "dashboard-item-1759906246155-lab-table",
        "type": "component",
        "x": 619,
        "y": 3701,
        "width": 520,
        "height": 500,
        "componentType": "LabTable",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Lab Findings",
            "component": "LabTable",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Mild ALT elevation",
                                "Possible MASLD flare"
                            ]
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Prior abnormal LFTs",
                                "Chronic liver disease risk"
                            ]
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "LFT normalization",
                                "Viral/autoimmune/metabolic workup negative"
                            ]
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "Stable labs",
                                "Safe to initiate MTX"
                            ]
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 185 U/L (4.6\u00d7 ULN)",
                                "Severe DILI warning",
                                "MTX toxicity suspected"
                            ]
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 490 U/L (12\u00d7 ULN)",
                                "Bilirubin 110 \u03bcmol/L",
                                "Severe acute DILI",
                                "Emergency admission"
                            ]
                        }
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Bilirubin 190 \u03bcmol/L (peak cholestasis)",
                                "Ongoing severe DILI",
                                "Inpatient hepatology"
                            ]
                        }
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:50:46.155Z",
        "updatedAt": "2025-11-21T08:36:42.289Z"
    },
    {
        "id": "dashboard-item-1759906246156-lab-chart",
        "type": "component",
        "x": 620,
        "y": 4304,
        "width": 520,
        "height": 500,
        "componentType": "LabChart",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Lab Trends",
            "component": "LabChart",
            "props": {
                "encounters": [
                    {
                        "encounter_no": 1,
                        "date": "2024-03-05",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "ALT 78 U/L",
                                "Mild hepatocellular elevation"
                            ]
                        }
                    },
                    {
                        "encounter_no": 2,
                        "date": "2024-04-01",
                        "meta": {
                            "ui_risk_color": "amber",
                            "event_tags": [
                                "Persistently abnormal LFTs",
                                "MASLD risk"
                            ]
                        }
                    },
                    {
                        "encounter_no": 3,
                        "date": "2024-05-06",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "ALT normalized (35 U/L)",
                                "Workup negative"
                            ]
                        }
                    },
                    {
                        "encounter_no": 4,
                        "date": "2024-06-03",
                        "meta": {
                            "ui_risk_color": "green",
                            "event_tags": [
                                "Stable labs",
                                "MTX initiation"
                            ]
                        }
                    },
                    {
                        "encounter_no": 5,
                        "date": "2024-07-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 185 U/L (4.6\u00d7 ULN)",
                                "Severe MTX toxicity warning"
                            ]
                        }
                    },
                    {
                        "encounter_no": 6,
                        "date": "2024-08-12",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "ALT 490 U/L (12\u00d7 ULN)",
                                "Bilirubin 110 \u03bcmol/L",
                                "Severe DILI"
                            ]
                        }
                    },
                    {
                        "encounter_no": 7,
                        "date": "2024-08-15",
                        "meta": {
                            "ui_risk_color": "red",
                            "event_tags": [
                                "Bilirubin 190 \u03bcmol/L (peak)",
                                "Ongoing severe DILI"
                            ]
                        }
                    }
                ],
                "medicationTimeline": [
                    {
                        "name": "Metformin",
                        "start": "2019-01-01",
                        "dose": "1000mg BD"
                    },
                    {
                        "name": "Ramipril",
                        "start": "2020-01-01",
                        "dose": "5mg daily"
                    },
                    {
                        "name": "Methotrexate",
                        "start": "2024-06-03",
                        "end": "2024-08-12",
                        "dose": "7.5mg weekly initially; reduced to 5mg weekly on 2024-07-15"
                    },
                    {
                        "name": "Folic Acid",
                        "start": "2024-06-03",
                        "dose": "5mg weekly"
                    },
                    {
                        "name": "N-Acetylcysteine (IV)",
                        "start": "2024-08-12",
                        "end": "2024-08-17",
                        "dose": "3-bag protocol"
                    },
                    {
                        "name": "Ursodeoxycholic Acid",
                        "start": "2024-08-15",
                        "dose": "500mg BID"
                    }
                ]
            }
        },
        "createdAt": "2025-10-14T16:50:46.156Z",
        "updatedAt": "2025-11-21T08:36:34.517Z"
    },
    {
        "id": "dashboard-item-1759906246157-differential-diagnosis",
        "type": "component",
        "x": 620,
        "y": 4911,
        "width": 520,
        "height": 500,
        "componentType": "DifferentialDiagnosis",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Differential Diagnosis",
            "component": "DifferentialDiagnosis",
            "props": {
                "patientData": {
                    "encounters": [
                        {
                            "encounter_no": 6,
                            "assessment": {
                                "impression": "Severe acute Drug-Induced Liver Injury (DILI) secondary to Methotrexate with developing cholestasis",
                                "differential": [
                                    "Methotrexate-induced hepatocellular DILI (most likely)",
                                    "Acute-on-chronic liver injury due to underlying MASLD/MASH",
                                    "Acute viral hepatitis (HBV/HCV unlikely but part of workup)",
                                    "Autoimmune hepatitis (screen previously negative)",
                                    "Mechanical biliary obstruction (excluded by ultrasound)",
                                    "Ischemic hepatitis (no shock, normal hemodynamics)",
                                    "Sepsis-associated liver injury (no fever or hemodynamic instability)"
                                ]
                            },
                            "rucam_ctcae_analysis": {
                                "rucam": {
                                    "rows": [
                                        [
                                            "1",
                                            "Time to onset from drug start",
                                            "MTX started 2024-06-03 \u2192 severe DILI by 2024-08-12 (\u224810 weeks)",
                                            "+2",
                                            "Typical 5\u201390 day window for idiosyncratic hepatocellular DILI."
                                        ],
                                        [
                                            "2",
                                            "Course after stopping drug",
                                            "ALT decreased from 490 \u2192 420 within 3 days of cessation",
                                            "+3",
                                            "Supports drug causality (fall \u226550% in <8 days expected)."
                                        ],
                                        [
                                            "5",
                                            "Exclusion of non-drug causes",
                                            "Viral hepatitis panel negative; autoimmune markers negative; ultrasound showed no obstruction",
                                            "+2",
                                            "Alternative causes convincingly excluded."
                                        ]
                                    ]
                                },
                                "reasoning": "The clinical pattern demonstrates severe hepatocellular injury with ALT 490 U/L, AST 350 U/L, and bilirubin >100 \u03bcmol/L. MTX exposure timeline fits perfectly for idiosyncratic hepatocellular DILI. Viral, autoimmune, and biliary causes were excluded through negative serology and normal biliary imaging. Hemodynamics remained stable, making ischemic hepatitis unlikely. No signs of infection to suggest sepsis-related liver injury. MASLD/MASH acted as a susceptibility factor but not the primary cause. Therefore, MTX toxicity remains the leading diagnosis."
                            }
                        }
                    ]
                }
            }
        },
        "createdAt": "2025-10-14T16:50:46.157Z",
        "updatedAt": "2025-11-21T08:36:38.002Z"
    },
    {
        "id": "dashboard-item-1759906300003-single-encounter-1",
        "type": "component",
        "x": -3300,
        "y": 800,
        "width": 400,
        "height": 500,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #1 - Outpatient Visit",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 1,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-03-05T10:15:22Z",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "General Practice"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Suboptimal control of T2DM/HTN, Chronic Fatigue Syndrome possibly related to MASLD. Diabetes control is poor with HbA1c at 58 mmol/mol, indicating long-standing hyperglycaemia and need for therapeutic adjustment.",
                        "differential": [
                            "T2DM suboptimal control",
                            "Hypertension suboptimal control",
                            "Chronic Fatigue Syndrome",
                            "MASLD"
                        ]
                    },
                    "chief_complaint": "Increased fatigue over the past 4-5 months",
                    "hpi": "Sarah Miller, a 43-year-old administrative assistant, presents with debilitating fatigue affecting work performance. She averages 6.5 hours of non-restorative sleep per night and experiences RA-related discomfort, particularly in the right wrist. She takes Ibuprofen 4-5 times per week for pain and chemically-induced frequent bloating. HbA1c from today\u2019s labs is 58 mmol/mol, confirming persistently weak glycaemic control which may be contributing to fatigue and metabolic strain.",
                    "medications_prior": [
                        {
                            "name": "Metformin",
                            "route": "Oral, unknown dose, BD frequency, for T2DM"
                        },
                        {
                            "name": "Ramipril",
                            "route": "Oral, 5mg, OD frequency, for Hypertension"
                        },
                        {
                            "name": "Ibuprofen",
                            "route": "Oral, unknown dose, taken 4-5 times per week for RA pain"
                        },
                        {
                            "name": "Simethicone",
                            "route": "Oral, unknown dose, unknown frequency, for bloating"
                        }
                    ],
                    "physical_exam": {
                        "general": "Appears non-toxic and well-perfused.",
                        "msk": "Mild effusion in right MCP joint 3, mild pain on movement.",
                        "other_systems": "Vital Signs: BP 146/92 mmHg (sitting), HR 82 bpm, RR 16/min, Temp 36.8\u00b0C, SpO\u2082 99% on room air. Anthropometrics: Height 1.64 m, Weight 86 kg (BMI 32.0 kg/m\u00b2; class I obesity). Weight reported as broadly stable over the past 12 months. Skin/Sclera: Anicteric sclerae; no chronic liver disease stigmata. Abdomen: Soft, lax, normal liver span, no tenderness. Diabetes: Persistent hyperglycaemia suspected based on elevated HbA1c and obesity."
                    },
                    "plan": {
                        "investigations": {
                            "labs": [
                                "Complete LFTs",
                                "HbA1c",
                                "Consider future intensification of diabetes therapy if HbA1c remains > 53 mmol/mol"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow-up in 4 weeks to evaluate LFTs and MTX eligibility.",
                            "medications_started": []
                        }
                    },
                    "reason_for_visit": "Increased fatigue"
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 1,
                "dataSource": "Electronic Health Record"
            }
        },
        "createdAt": "2025-10-14T16:55:00.003Z",
        "updatedAt": "2025-10-14T16:55:00.003Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-2",
        "type": "component",
        "x": -2700,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #2 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 2,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-04-01T15:00:45",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Elevated ALT of 78 U/L, concerning for hepatocellular inflammation, potentially related to Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD). Methotrexate initiation deferred pending further investigation.",
                        "differential": [
                            "Hepatocellular inflammation",
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Viral Hepatitis",
                            "Autoimmune Hepatitis",
                            "Hemochromatosis",
                            "Alpha-1-Antitrypsin Deficiency"
                        ]
                    },
                    "chief_complaint": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment.",
                    "hpi": "Patient reports making small changes to diet and activity since the last visit, with an approximate 0.5\u20131 kg weight loss. The elevated ALT of 78 U/L was reviewed. Potential Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) was discussed as a contributing factor. Patient was educated on the significance of these results and the potential risk for liver injury if starting Methotrexate without further clearance.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 142/90 mmHg (sitting), HR 80 bpm, RR 16/min, Temp 36.7\u00b0C, SpO\u2082 99% on room air. Anthropometrics: Weight 85.5 kg (BMI 31.8 kg/m\u00b2).",
                        "msk": "",
                        "other_systems": ""
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "HBsAg",
                                "HCV Ab",
                                "ANA",
                                "ASMA",
                                "Ferritin",
                                "TIBC",
                                "Full liver panel"
                            ]
                        },
                        "management": {
                            "follow_up": "Return for follow-up in 4 weeks to review investigation results. Continued monitoring and lifestyle modifications advised.",
                            "medications_started": []
                        }
                    },
                    "reason_for_visit": "Review of abnormal liver function tests and planning for rheumatoid arthritis treatment."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 2,
                "dataSource": "BigHand"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-3",
        "type": "component",
        "x": -2000,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #3 - Outpatient Follow-up",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 3,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-05-06T09:00:10",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Follow-up regarding normalization of liver function tests and initiation of Methotrexate for rheumatoid arthritis management. Normalization of LFTs with ALT at 35 U/L. Negative workup for chronic liver conditions. Likely transient elevation possibly related to MASLD. Cleared for Methotrexate initiation.",
                        "differential": [
                            "Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)",
                            "Acute self-limiting liver episode"
                        ]
                    },
                    "chief_complaint": "Follow-up regarding normalization of liver function tests (LFTs) and potential initiation of Methotrexate for rheumatoid arthritis management.",
                    "hpi": "Since the previous review, Sarah reports increased adherence to dietary advice and gentle walking most days, noting a ~1.5 kg weight loss since March. Comprehensive hepatitis workup (viral, autoimmune, metabolic) returned negative. ALT has decreased to 35 U/L, suggesting transient elevation. Patient is considered low-risk for MTX initiation.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 140/88 mmHg (sitting), HR 78 bpm, RR 15/min, Temp 36.6\u00b0C, SpO\u2082 99% on room air.",
                        "msk": "",
                        "other_systems": "Anthropometrics: Weight 84 kg (BMI 31.2 kg/m\u00b2)."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "LFTs every 6 weeks",
                                "FBC every 6 weeks"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow-up appointment set for early August to review treatment response, adherence to monitoring, and adjust plan. Instructed to begin Methotrexate on 2024-06-03. Emphasized adherence to strict 6-weekly monitoring schedule.",
                            "medications_started": [
                                {
                                    "dose": "7.5mg",
                                    "frequency": "weekly",
                                    "name": "Methotrexate",
                                    "route": "Unknown"
                                },
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Folic acid",
                                    "route": "Unknown"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Follow-up for liver function tests and rheumatoid arthritis management."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 3,
                "dataSource": "Electronic Health Record"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-4",
        "type": "component",
        "x": -1300,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #4 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 4,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-06-03T11:30:55",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Unknown"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Initiation of Methotrexate for Rheumatoid Arthritis management.",
                        "differential": []
                    },
                    "chief_complaint": "Initiation of Disease-Modifying Anti-Rheumatic Drug (DMARD) - Methotrexate (MTX) for Rheumatoid Arthritis (RA) management.",
                    "hpi": "Sarah Miller presents for the initiation of Methotrexate treatment for RA. She reports her joint pain has been stable but remains a significant source of discomfort, affecting her daily activities. A thorough review of her medical history, medication adherence, and lifestyle was conducted. The patient confirms receipt and comprehension of the Methotrexate informational leaflet, indicating understanding of the treatment regimen and potential adverse effects. The decision to commence Methotrexate was made following normalization of liver function tests (LFTs) as of May 6, 2024. The patient reiterated understanding of the importance of strict compliance with the monitoring schedule due to the severe hepatotoxicity risk associated with Methotrexate.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 138/86 mmHg (sitting), HR 80 bpm, RR 15/min, Temp 36.7\u00b0C, SpO\u2082 98% on room air. Anthropometrics: Weight 84 kg (BMI 31.2 kg/m\u00b2). Weight stable compared with early May.",
                        "msk": "",
                        "other_systems": ""
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "LFTs every six weeks",
                                "Full Blood Count (FBC) every six weeks"
                            ]
                        },
                        "management": {
                            "follow_up": "First LFT/FBC evaluation scheduled for July 15, 2024. Regular monitoring every six weeks for the next 6 months. Patient to contact clinic immediately if severe nausea, vomiting, or jaundice occur.",
                            "medications_started": [
                                {
                                    "dose": "7.5mg",
                                    "frequency": "once weekly",
                                    "name": "Methotrexate",
                                    "route": "orally"
                                },
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Folic Acid",
                                    "route": "orally"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Initiation of Methotrexate for Rheumatoid Arthritis management."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 4,
                "dataSource": "Medilogik"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-5",
        "type": "component",
        "x": -600,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #5 - Outpatient",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 5,
                    "meta": {
                        "visit_type": "Outpatient",
                        "date_time": "2024-07-15T14:00:30",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "Rheumatology"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Methotrexate-induced Drug-Induced Liver Injury (DILI) presenting with elevated ALT (185 U/L, 4.6x ULN), with new intermittent nausea and increased fatigue. Rheumatoid arthritis symptoms are improving on Methotrexate. Diabetes control has deteriorated with HbA1c rising to 60 mmol/mol, signalling worsening glycaemia during MTX therapy and possible contribution to fatigue.",
                        "differential": [
                            "Methotrexate-induced Drug-Induced Liver Injury (DILI)",
                            "Underlying MASLD risk factors"
                        ]
                    },
                    "chief_complaint": "Routine Methotrexate (MTX) monitoring. Reports of new intermittent nausea and increased fatigue.",
                    "hpi": "Sarah Miller, a 43-year-old female, presents for routine Methotrexate monitoring. She reports ~1 kg unintentional weight loss over the past month, attributed to reduced appetite and intermittent nausea, primarily in the evenings. No vomiting or diarrhea. Fatigue levels have returned to pre-MTX initiation severity. Rheumatoid arthritis symptoms have significantly improved with diminished joint pain and increased daily function since starting Methotrexate. Recent labs show ALT elevated to 185 U/L (4.6x ULN). HbA1c has worsened to 60 mmol/mol, indicating declining diabetes control despite weight loss.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Vital Signs: BP 144/92 mmHg (sitting), HR 88 bpm, RR 16/min, Temp 36.8\u00b0C, SpO\u2082 98% on room air.",
                        "msk": "Joint pain has diminished.",
                        "other_systems": "Weight 83 kg (BMI 30.8 kg/m\u00b2). Despite some weight reduction, diabetes control is worsening with higher HbA1c and increased metabolic fatigue."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [],
                            "labs": [
                                "Repeat liver function tests in four weeks",
                                "HbA1c monitoring recommended due to recent deterioration"
                            ]
                        },
                        "management": {
                            "follow_up": "Follow up in four weeks. Advised to remain vigilant for any worsening of symptoms or new signs of liver dysfunction such as jaundice, further exacerbated fatigue, or darker urine. Ensure adherence to adjusted Methotrexate regimen. Attend Hepatology consultation.",
                            "medications_started": [
                                {
                                    "dose": "5mg",
                                    "frequency": "weekly",
                                    "name": "Methotrexate",
                                    "route": ""
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Routine Methotrexate monitoring and management of new symptoms of nausea and fatigue, and elevated liver enzymes."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 5,
                "dataSource": "Nervecentre"
            }
        },
        "createdAt": "2025-10-15T08:00:00.000Z",
        "updatedAt": "2025-10-15T08:00:00.000Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-6",
        "type": "component",
        "x": 100,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #6 - Urgent Review",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 6,
                    "meta": {
                        "visit_type": "Emergency Department (ED)",
                        "date_time": "2024-08-12T14:00:00",
                        "provider": {
                            "name": "Dr. P. Stevens",
                            "specialty": "General Practitioner"
                        },
                        "ui_risk_color": "red"
                    },
                    "assessment": {
                        "impression": "Severe, Acute Drug-Induced Liver Injury (DILI) with developing cholestasis.",
                        "differential": [
                            "Mechanical obstruction (e.g., choledocholithiasis)"
                        ]
                    },
                    "chief_complaint": "Urgent review for new onset jaundice, dark urine, and constant, severe nausea leading to anorexia.",
                    "hpi": "Patient presented with new onset jaundice, dark urine, and severe nausea leading to anorexia. Initial ED vital signs: BP 132/88 mmHg (sitting), HR 102 bpm, RR 18/min, Temp 37.3\u00b0C, SpO\u2082 97% on room air. Weight 81.5 kg (BMI 30.3 kg/m\u00b2). Patient reported significant weight loss of approximately 4.5 kg over the past 4\u20136 weeks due to nausea and anorexia. Jaundice noted upon waking, dark urine observed. Symptoms are severe and persistent. Laboratory analysis revealed significantly elevated ALT levels and bilirubin of 110 \u03bcmol/L, indicating severe cholestasis. INR was stable at 1.1.",
                    "medications_prior": [
                        {
                            "name": "Methotrexate",
                            "route": "Oral"
                        }
                    ],
                    "physical_exam": {
                        "general": "Jaundice noted. Patient appears anorectic."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [
                                "USG Abdomen Complete - STAT (Accession Number: USG-240812-001). Report indicates severe MASH/MASLD, no mechanical obstruction. Impression: Severe hepatocellular DILI superimposed on advanced chronic liver disease (MASH)."
                            ],
                            "labs": [
                                "ALT levels elevated",
                                "Bilirubin levels elevated to 110 \u03bcmol/L",
                                "INR stable at 1.1"
                            ]
                        },
                        "management": {
                            "follow_up": "Close follow-up post-hospital discharge to reassess liver function and re-evaluate RA treatment plan, considering contraindication for future Methotrexate use.",
                            "medications_started": [
                                {
                                    "name": "N-acetylcysteine (NAC)",
                                    "route": "IV Infusion (3-bag protocol, 85kg weight)"
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "New onset jaundice, dark urine, severe nausea, and anorexia, concerning for acute liver injury."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 1,
                "dataSource": "ICE/VueExplore"
            }
        },
        "createdAt": "2025-10-14T16:55:00.004Z",
        "updatedAt": "2025-10-14T16:55:00.004Z"
    },
    {
        "id": "dashboard-item-1759906300004-single-encounter-7",
        "type": "component",
        "x": 800,
        "y": 800,
        "width": 500,
        "height": 600,
        "componentType": "SingleEncounterDocument",
        "color": "#ffffff",
        "description": "",
        "content": {
            "title": "Encounter #7 - Inpatient Hepatology Ward B",
            "component": "SingleEncounterDocument",
            "props": {
                "encounter": {
                    "encounter_no": 7,
                    "meta": {
                        "visit_type": "Inpatient",
                        "date_time": "2024-08-15T10:00:48",
                        "provider": {
                            "name": "Dr. R. Sharma",
                            "specialty": "Consultant Hepatologist"
                        },
                        "ui_risk_color": "yellow"
                    },
                    "assessment": {
                        "impression": "Severe Drug-Induced Liver Injury (DILI) secondary to Methotrexate, with a RUCAM score of 9/10, indicating a high likelihood of causation. No features of Acute-on-Chronic Liver Failure (ACLF). Underlying Metabolic Associated Steatotic Hepatitis (MASH).",
                        "differential": []
                    },
                    "chief_complaint": "Severe Drug-Induced Liver Injury (DILI)",
                    "hpi": "The patient is reviewed on Day 3 of her hospital admission following severe DILI. Methotrexate was stopped immediately upon recognizing it as the causative agent. Sarah remains significantly jaundiced; however, nausea has shown slight improvement since admission. Vital neurological signs include a stable Glasgow Coma Scale (GCS) score of 15, with no evidence of hepatic encephalopathy (HE); absence of asterixis or cognitive impairment. The ALT level, though elevated at 420 U/L, is beginning to decline, suggesting a positive response to the cessation of Methotrexate. Crucially, the INR remains stable at 1.1, indicating preserved liver synthetic function. These clinical findings collectively confirm a diagnosis of severe, cholestatic DILI in a patient with underlying Metabolic Associated Steatotic Hepatitis (MASH), markedly susceptible to hepatotoxic insults.",
                    "medications_prior": [],
                    "physical_exam": {
                        "general": "Sarah exhibits pronounced jaundice, evidenced by a total bilirubin level of 190 \u03bcmol/L. Despite this, she appears alert and reports moderate comfort under current care measures. Vital Signs (ward review): BP 128/82 mmHg, HR 96 bpm, RR 16/min, Temp 37.0\u00b0C, SpO\u2082 97% on room air. Anthropometrics: Weight 81 kg (BMI 30.1 kg/m\u00b2). No significant interval weight change since admission.",
                        "msk": "",
                        "other_systems": "CNS Examination: She is fully oriented, demonstrating no neurological deficits. GCS remains a reassuring 15 with negative neurological signs including asterixis, tremor, and speech abnormalities. Cardio/Pulmonary: Vital signs are stable with no indications of fluid overload, pulmonary distress, or hepatorenal syndrome. Abdominal Examination: The abdomen is soft and non-tender. The liver edge is not easily palpable due to Sarah's body habitus, yet no tenderness is detected upon examination."
                    },
                    "plan": {
                        "investigations": {
                            "imaging": [
                                "Fibroscan in three months"
                            ],
                            "labs": [
                                "Daily INR evaluations until ALT levels fall below 150 U/L",
                                "Neurological assessments every four hours"
                            ]
                        },
                        "management": {
                            "follow_up": "Arrange a Fibroscan (Liver Stiffness Measurement) in three months to assess fibrosis arising from chronic MASH and the acute DILI event. Coordinate with Rheumatology for the initiation of a non-hepatotoxic DMARD alternative, such as Hydroxychloroquine or a biologic, to manage RA without compromising liver health.",
                            "medications_started": [
                                {
                                    "dose": "500mg",
                                    "frequency": "twice daily",
                                    "name": "Ursodeoxycholic Acid (UDCA)",
                                    "route": ""
                                },
                                {
                                    "dose": "",
                                    "frequency": "",
                                    "name": "Folic Acid",
                                    "route": ""
                                }
                            ]
                        }
                    },
                    "reason_for_visit": "Review on Day 3 of hospital admission following severe DILI."
                },
                "patient": {
                    "name": "Sarah Miller",
                    "sex": "Female",
                    "age_at_first_encounter": 43
                },
                "encounterIndex": 7,
                "dataSource": "Nervecentre"
            }
        },
        "createdAt": "2025-10-14T16:55:00.004Z",
        "updatedAt": "2025-10-14T16:55:00.004Z"
    },
    {
        "id": "iframe-item-easl-interface",
        "type": "iframe",
        "x": 1100,
        "y": 7800,
        "width": 1800,
        "height": 1200,
        "title": "EASL Web Interface",
        "iframeUrl": "https://easl-board.vercel.app/",
        "color": "#ffffff",
        "rotation": 0,
        "conversationHistory": [],
        "createdAt": "2025-10-28T12:00:00.000Z",
        "updatedAt": "2025-10-28T12:00:00.000Z"
    },
    {
        "id": "dashboard-item-chronomed-2",
        "type": "component",
        "x": -2351,
        "y": 3706,
        "width": 2200,
        "height": 900,
        "componentType": "Chronomed2Dashboard",
        "color": "#ffffff",
        "description": "This timeline functions similarly to a medication timeline, but with an expanded DILI assessment focus. It presents a chronological view of the patient\u2019s clinical course, aligning multiple time-bound elements to support hepatotoxicity monitoring. Like the medication timeline tracks periods of drug exposure, this object also visualises medication start/stop dates, dose changes, and hepatotoxic risk levels. In addition, it integrates encounter history, longitudinal liver function test trends, and critical clinical events. Temporal relationships are highlighted to show how changes in medication correlate with laboratory abnormalities and clinical deterioration, providing causality links relevant to DILI analysis. The timeline is designed to facilitate retrospective assessment and ongoing monitoring by showing when key events occurred in relation to medication use and liver injury progression.",
        "content": {
            "title": "Chronomed Dashboard 2",
            "component": "Chronomed2Dashboard",
            "props": {}
        },
        "createdAt": "2025-11-21T12:00:00.000Z",
        "updatedAt": "2025-11-21T08:36:21.644Z"
    }
]